Source BioScience, a UK provider of services to the life science, pharma biotech and healthcare sectors, has purchased a further two Illumina Genome Analyzer IIx devices to enhance its DNA sequencing service in an investment of
Source BioScience, a UK provider of services to the life science, pharma biotech and healthcare sectors, has purchased a further two Illumina Genome Analyzer IIx devices to enhance its DNA sequencing service in an investment of £700,000.
The company's DNA sequencing solution is based on a combination of Sanger and next-generation sequencing with bioinformatic support. The company says the enhanced portfolio will provide greater flexibility and encourage the development of new applications.
Source BioScience already operates DNA sequencing laboratories in four academic centres across the UK (at Nottingham University; University College London; Cambridge University and Oxford University) and this additional investment will be at Nottingham.
The Illumina technology complements Source BioScience's portfolio of genomic and diagnostic systems, which have applications in life science research, molecular pathology and clinical diagnostics.
The company has been awarded CSPro certified service provider status by Illumina, one of only ten laboratories in the world.
Nick Ash, managing director of Source BioScience, said: "This additional investment in the Genome Analyzer will establish Source BioScience as one of the leading commercial service providers of Illumina sequencing technology in Europe."
The company has now invested a total of £1,200,000 in three Genome Analyzer sequencing machines and one Beadstation genotyping platform plus peripherals.
Ash added that the company would be introducing Illumina's newly launched HiSeq 2000 high throughput sequencing platform, which complements the Genome Analyzer, during the course of 2010.